📰 Ysopia Bioscience News
Ysopia Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ysopia Bioscience. Real-time updates on events, politics, business and more.
April 24, 2023
/PRNewswire/ -- The "Microbiome Therapeutics: Global Markets" report has been added to ResearchAndMarkets.coms offering. The report provides a comprehensive...
March 24, 2023
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 -- Celyad Oncology , a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, is pleased to announce... | March 24, 2023
March 24, 2023
24.03.2023 - Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief ... Seite 1
March 24, 2023
Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased
February 10, 2023
/PRNewswire/ -- The "Microbiome Therapeutics: Global Markets" report has been added to ResearchAndMarkets.coms offering. The global Microbiome Therapeutics...
May 28, 2021
With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the goal of priming the translational pump in hot areas where European academics have already made a mark, particularly the microbiome.